EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Zai Lab's enterprise value is $2,568.3 Mil.
Zai Lab's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was $-327.9 Mil. Therefore, Zai Lab's EV-to-EBITDA for today is -7.83.
The historical rank and industry rank for Zai Lab's EV-to-EBITDA or its related term are showing as below:
ZLAB'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -56.33 Med: -9.83 Max: -2.08
Current: -7.83
During the past 9 years, the highest EV-to-EBITDA of Zai Lab was -2.08. The lowest was -56.33. And the median was -9.83.
ZLAB's EV-to-EBITDA is ranked worse than 100% of 439
companies
in the Biotechnology industry
Industry Median: 9.55
vs ZLAB: -7.83
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-10-31), Zai Lab's stock price is $30.223.
Zai Lab's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was $-3.000. Therefore, Zai Lab's PE Ratio (TTM) for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Zai Lab EV-to-EBITDA Historical Data
The historical data trend for Zai Lab's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Zai Lab's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zai Lab's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zai Lab's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Zai Lab's EV-to-EBITDA falls into.
Zai Lab EV-to-EBITDA Calculation
Zai Lab's EV-to-EBITDA for today is calculated as:
Zai Lab's current Enterprise Value is $2,568.3 Mil.
Zai Lab's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-327.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zai Lab (NAS:ZLAB) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Zai Lab's share price for today is $30.223.
Zai Lab's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Thank you for viewing the detailed overview of Zai Lab's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ZLAB has been successfully added to your 